









Markets
/
Stocks
/
nasdaq-tcrx
/

TScan Therapeutics Inc

TCRX

View Detailed Chart

1.680USD

+0.060+3.70%

Market hours （ET）Quotes delayed by 15 min

95.07MMarket Cap

LossP/E TTM



TScan Therapeutics Inc

1.680

+0.060+3.70%

Overview Company Financials

Financials

Intraday

30m

Today

+3.70%

5 Days

-12.95%

1 Month

+11.26%

6 Months

-30.86%

Year to Date

-44.74%

1 Year

-74.96%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

BUY

Current Rating

8.500

Target Price

424.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

TScan Therapeutics Inc

TCRX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(2)

Buy(2)

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.057

Neutral

RSI(14)

42.876

Neutral

STOCH(KDJ)(9,3,3)

12.370

Sell

ATR(14)

0.124

Low Volatility

CCI(14)

-267.371

Oversold

Williams %R

95.385

Oversold

TRIX(12,20)

0.624

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.768

Sell

MA10

1.818

Sell

MA20

1.802

Sell

MA50

1.640

Buy

MA100

1.540

Buy

MA200

2.507

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

Ticker SymbolTCRX

CompanyTScan Therapeutics Inc

CEOMr. Gavin Macbeath, Ph.D.

Websitehttps://www.tscan.com